Uxin Ltd ADRUXIN
Price$1.32

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $463.3M+126.2% YoYTTM through 31 Dec 2025
Net Income -$37.5MTTM through 31 Dec 2025
Free Cash Flow -$75.2MTTM through 31 Dec 2025

Margins

Current
Gross Margin7.0%
EBITDA Margin-5.1%
Operating Margin-5.4%
Net Margin-8.1%

Returns

113.7%ROE
-14.0%ROA

Balance Sheet Health

Debt / Equity-5.46x
Current Ratio0.79x
Net Debt$1.4B
Cash & Equivalents$11.9M

Quality Metrics

Altman Z-Score-10.07
Piotroski F-Score5 / 9
FCF Margin-16.2%

Multi-Year Trend

Revenue
'18'19'21'22'23'24'25
FY2025: $3.2B
Diluted EPS$0.00TTM
'18'19'21'22'23'24
FY2024: $-0.17

Dividend

No dividend

Capital Allocation

R&D Spend$1.8M
Capex Intensity0.7%
Financials converted at 6.9961 from RMB.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.